COMPARISON OF TWO DOSAGE REGIME OF KETOCONAZOLE IN THE TREATMENT OF PITYRIASIS VERSICOLOR (PV)
Main Article Content
Objective: To evaluate the efficacy and safety of single dose (400 mg) of Ketoconazole versus 10 days 200
mg daily dose of Ketoconazole in the treatment of Pityriasis Versicolor in patients attending out patient
department of Hayatabad Medical Complex, Peshawar.
Material and Methods: Patients suffering from extensive PV who had not received any other treatment in the last 2
months and having no history of liver disease were selected for this trial. 90 patients (age ranging from 12 to 40 years in
both groups) were enrolled for the study during April 2006 till end September 2006. Liver function tests were done before starting treatment, and at intervals of 3 weeks and 6 weeks after therapy. Diagnosis of PV was made on clinical
appearance and confirmed by Wood's light examination and KOH examination of mycological scrapings. Patients were
divided into 2 groups, A and B. Group A received 200mg of Ketoconazole for 10 days whereas, patients in group B
received single 400mg dose.
Results: Fifty male patients and 30 female patients completed the study in both groups. 20 patients (50 %) in group A
(200 mg daily Ketoconazole for 10 days) had negative mycological and Wood's lamp examination after 3 weeks and 35
patients (87.5%) had negative mycological and Wood's lamp examination after 6 weeks of stopping therapy. While 10
patients (25%) in-group B (400 mg Ketoconazole as single dose) had negative Wood's lamp and mycological cure after
3 weeks while 25 patients (62.5%) had Wood's lamp and mycological cure after 6 weeks of stopping therapy treatment
was well tolerated in both groups and none reported any untoward side effects during or after stopping treatment..
Conclsuion: Ketoconazole 200 mg daily for 10 days was found to be more effective in the treatment of PVas compare
to single dose therapy of 400mg. However studies involving much larger patients sample are needed to establish the
superiority of one form of treatment over the other.
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.